Business Wire

NTT

Share
NTT Group Launches Compliance Management Solution Using Robotic Process Automation (RPA)

In recent times, there has been a growing demand for companies worldwide to strengthen their compliance and risk management. To help our clients manage these requirements, NTT Group, represented by NTT Advanced Technology Corporation (hereinafter, NTT-AT), Everis Spain S.L.U. (hereinafter, everis) of NTT DATA Corporation, itelligence AG (hereinafter, itelligence) of NTT DATA Corporation are announcing a compliance management solution using robotic process automation (RPA). This solution aggregates and analyses data from internal HR and compliance on-premise and cloud-based systems, supporting customer initiatives to strengthen responsibility and internal governance control. The NTT Group plans to start providing this service in the second quarter of 2020.

Due to stricter regulations across many industries, particularly the financial industry, businesses are facing the threat of multi-regime controls and high fines by local authorities. Due to the complexity of the regulations and reporting requirements, these institutions are facing problems to identify compliance issues, along with a lack of transparency in governance. This often leads to increased manual workload, process time and paperwork due to the complexity of their IT environment.

The integrated solution provided by NTT Group combines; the RPA tool "WinActor ® (*1) " of NTT-AT, the SMCR solution of everis, and the consulting and the integration capabilities of itelligence to achieve the combination of reducing complex manual operations and coordination of compliance-related data managed across multiple systems, such as Excel (*2) and existing systems.

This solution will initially be provided as a compliance management solution for the “Senior Managers and Certification Regime (SMCR)" in the UK and will be expanded outside the UK in response to regulations and to support clients compliance and governance management globally.

NTT helps its clients accelerate their digital transformation journey by implementing innovative technologies, such as WinActor® .

Notes:

About "WinActor® "
WinActor is a robotic process automation (RPA) tool which has been developed using the in-house technologies by NTT Access Network service system laboratories and has been achieved into commercialization.
WinActor records and automates various types of human operations such as those via Windows (*2) application, Web Application and so on. It runs automatically routine repetitive tasks and large volume works instead of or collaborating with human. Additionally, by changing the existing jobs into new automatic work style, it would bring out a large value in business perspective such as efficiency, quality and cost effectiveness without modifying any software of existing system.
WinActor has been rapidly introduced and spread since 2017 especially in the organizations which seek for “Work style revolution” regardless the type of industry and size of the company. Currently, in November end of 2019, more than 4,200 companies have introduced WinActor.
For more information, please refer to https://winactor.biz/ .

(*1) "WinActor" is a registered trademark of NTT Advanced Technology Corporation.
(*2) "Excel", “Windows” is registered trademarks or trademarks of Microsoft Corporation in the US and/or other countries.

About NTT
For more information on NTT, visit www.global.ntt/
For more information on NTT-AT, visit www.ntt-at.com/
For more information on everis, visit www.everis.com/global/en
For more information on itelligence, visit itelligencegroup.com/us/
For more information on the solution, visit uk.nttdata.com/SMCR

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release

Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release

- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o

SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release

Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product

Macnica Appoints Sebastien Dignard as CEO of Atlantic Region to Accelerate Global Component-to-Solutions and Vertical Strategy5.1.2026 12:00:00 CET | Press release

Macnica leader to strengthen cross-regional collaboration across the Americas and Europe Macnica Inc. today announced the promotion of Sebastien Dignard to chief executive officer of the company’s Atlantic region. In this role, Dignard will lead Macnica’s business across North America, Europe and South America, accelerating the company’s component-to-solutions strategy and strengthening cross-regional collaboration to deliver long-term value for customers and partners across key verticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105529342/en/ Sebastien Dignard, CEO, Macnica Atlantic Region Dignard previously served as president of Macnica Americas for two years where he led the organization through a period of growth and transformation across semiconductors, imaging, networking and advanced technologies. Under his leadership, the company shifted from a focus on individual components to value-driven solutions, ecosy

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye